Premium
A retrospective comparative outcome analysis following systemic therapy in M ycosis fungoides and S ezary syndrome
Author(s) -
Hanel Walter,
Briski Robert,
Ross Charles W.,
Anderson Thomas F.,
Kaminski Mark S.,
Hristov Alexandra C.,
Wilcox Ryan A
Publication year - 2016
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24564
Subject(s) - medicine , mycosis fungoides , retrospective cohort study , oncology , disease , chemotherapy , clinical endpoint , clinical trial , lymphoma
Cutaneous T‐cell lymphomas (CTCL), with few exceptions, remain incurable and treatment is largely palliative. We performed a retrospective analysis of systemic treatment outcomes of patients diagnosed with MF/SS. We identified 223 patients with MF/SS evaluated at a single institution from 1997 to 2013. Disease stage at diagnosis, time of treatment, and treatments received were retrospectively analyzed using our CTCL database. The primary endpoint was time to next treatment (TTNT). Treatment outcomes were analyzed using Kaplan–Meier method and comparisons among groups were made using log‐rank analysis. A superior TTNT was associated with retinoid or interferon therapies when compared with HDAC inhibitors or systemic chemotherapy. Retinoids and interferon were associated with superior TTNT in both limited‐stage and advanced stage disease. Extracorporeal photophoresis (ECP) had a superior TTNT in Sezary Syndrome. HDAC inhibitors and chemotherapy were associated with inferior TTNT in both limited stage disease and advanced stage disease. With the exception of interferon, retinoids, or ECP, durable responses are rarely achieved with systemic therapies in MF/SS patients, particularly those with advanced‐stage disease. Therefore, clinical trial participation with novel agents should be encouraged. Am. J. Hematol. 91:E491–E495, 2016. © 2016 Wiley Periodicals, Inc.